Cipla Limited Stock Price Today (NSE: CIPLA)
Fundamental Score
Cipla Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Cipla Limited share price today is ₹1431.10, down 1.30% on NSE/BSE as of 24 August 2026. Cipla Limited (CIPLA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.16L (Cr). The 52-week high for CIPLA share price is ₹1673.00 and the 52-week low is ₹1170.00. At a P/E ratio of 34.45x, CIPLA is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.82% and a debt-to-equity ratio of 0.01.
Cipla Limited Share Price Chart — NSE/BSE Historical Performance
Cipla Limited share price chart: -2.80% return over the past month. 52-week high ₹1673.00, 52-week low ₹1170.00.
Cipla Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1431.50 | ₹1437.60 | ₹1428.40 | ₹1431.10 | 5.89L (Cr) | |
| ₹1457.50 | ₹1474.30 | ₹1449.20 | ₹1450.00 | 7.85L (Cr) | |
| ₹1458.10 | ₹1464.40 | ₹1456.20 | ₹1458.80 | 4.41L (Cr) | |
| ₹1460.00 | ₹1468.80 | ₹1456.10 | ₹1463.00 | 6.21L (Cr) | |
| ₹1466.10 | ₹1469.80 | ₹1457.20 | ₹1463.00 | 9.59L (Cr) | |
| ₹1463.80 | ₹1483.70 | ₹1462.00 | ₹1467.70 | 6.63L (Cr) | |
| ₹1477.00 | ₹1477.00 | ₹1462.10 | ₹1463.80 | 7.65L (Cr) | |
| ₹1461.00 | ₹1488.10 | ₹1461.00 | ₹1477.00 | 14.62L (Cr) | |
| ₹1460.00 | ₹1463.00 | ₹1443.50 | ₹1458.80 | 9.74L (Cr) | |
| ₹1469.60 | ₹1469.60 | ₹1449.30 | ₹1460.00 | 9.47L (Cr) |
Cipla Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1475.00 | ₹1488.10 | ₹1428.40 | ₹1431.10 | -2.98% | |
| ₹1468.00 | ₹1491.20 | ₹1366.10 | ₹1473.20 | +0.35% | |
| ₹1410.00 | ₹1490.10 | ₹1341.10 | ₹1465.40 | +3.93% | |
| ₹1320.00 | ₹1444.50 | ₹1274.70 | ₹1401.00 | +6.14% | |
| ₹1255.00 | ₹1329.80 | ₹1170.00 | ₹1309.60 | +4.35% | |
| ₹1313.00 | ₹1354.50 | ₹1215.00 | ₹1224.20 | -6.76% | |
| ₹1330.00 | ₹1381.30 | ₹1293.10 | ₹1348.20 | +1.37% | |
| ₹1512.00 | ₹1539.70 | ₹1281.70 | ₹1324.00 | -12.43% | |
| ₹1532.00 | ₹1536.30 | ₹1475.90 | ₹1511.30 | -1.35% | |
| ₹1502.90 | ₹1538.40 | ₹1490.30 | ₹1531.30 | +1.89% | |
| ₹1505.00 | ₹1673.00 | ₹1490.80 | ₹1501.30 | -0.25% | |
| ₹1589.40 | ₹1599.00 | ₹1475.20 | ₹1503.30 | -5.42% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Cipla is a complex generics play with India as a safety net; USFDA setbacks or domestic margin compression will crush the stock.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Cipla received USFDA approval for Nintedanib Capsules for Idiopathic Pulmonary Fibrosis. The company is set for immediate launch, targeting a $3.76 billion market. Also, Cipla allotted 1,954 equity shares under employee stock option schemes.
CORE STORY (THE REAL GAME)
Cipla is transitioning from generics to complex generics and specialty products, particularly in the US market, while maintaining dominance in the Indian respiratory market. The key is navigating US pricing pressures and regulatory hurdles while leveraging its India business for stability.
- USFDA approval for Nintedanib Capsules
- Strong position in the Indian respiratory market
- Growth in chronic therapies
- Successful US generics launches
- Strong Q4 FY26 earnings
- Resolution of US tariff uncertainty
- Promoter holding below 40%
- US tariff risks
- Pricing pressure in US generics market
FII decreased holdings by 0.7%, DII increased holdings by 1.0%.
Indian pharma industry projected to reach $130 billion by 2030, driven by global demand and innovation.
Yes. Free Cash Flow 5Y: ₹14019.84 Cr.
Cipla needs to execute on US launches and maintain India momentum. Watch for Q4 FY26 results and US regulatory updates.
Primary Thesis Risk
Failure to execute on US complex generics pipeline.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Cipla Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cipla Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CIPLA across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (15.67%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (23.55%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (97.04x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.44)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹13261.59 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 54.26%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Profit Decline Concern (-39.19%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Low Promoter Commitment (29.21%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Cipla Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Cipla Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Cipla LimitedCipla Limited...Selected✓ CIPLA • 500087 | 40.2/100 | ₹1431.10₹1431 | ₹116131.81₹116131.81 | 34.45Average 34.5 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹7386.50₹7387 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹437.95₹438 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 62.3/100 | ₹28900.00₹28900 | ₹58692.31₹58692.31 | 37.82Average 37.8 Average | 34.46%Excellent 34.46% Excellent | 44.89%Excellent 44.89% Excellent | 0.04Excellent 0.0 Excellent | 17.57%Excellent 17.57% Excellent | 9.96%Good 9.96% Good | 1.90% |
JB Chemicals & Pharmaceuticals LtdJB Chemicals & ... JBCHEPHARM • 506943 | 53.9/100 | ₹2408.90₹2409 | ₹40248.14₹40248.14 | 56.02Average 56.0 Average | 18.93%Good 18.93% Good | 25.45%Excellent 25.45% Excellent | 0.00Excellent 0.0 Excellent | 12.37%Good 12.37% Good | 15.22%Excellent 15.22% Excellent | 0.88% |
Wockhardt LtdWockhardt Ltd... WOCKPHARMA • 532300 | 24.6/100 | ₹1953.40₹1953 | ₹30725.07₹30725.07 | 108.16Average 108.2 Average | 6.11%Poor 6.11% Poor | 7.55%Poor 7.55% Poor | 0.45Excellent 0.5 Excellent | -19.25%Poor -19.25% Poor | 4.49%Average 4.49% Average | 0.00% |
ACUTAAS CHEMICALS LIMITEDACUTAAS CHEMICA... ACUTAAS • 543349 | 62.09999999999999/100 | ₹3659.60₹3660 | ₹29036.77₹29036.77 | 81.50Average 81.5 Average | 24.05%Excellent 24.05% Excellent | 31.56%Excellent 31.56% Excellent | 0.02Excellent 0.0 Excellent | 45.77%Excellent 45.77% Excellent | 31.50%Excellent 31.50% Excellent | 0.04% |
Sequent Scientific LtdSequent Scienti... SEQUENT • 512529 | 63.9/100 | ₹188.78₹189 | ₹12241.20₹12241.20 | 61.29Average 61.3 Average | 11.05%Average 11.05% Average | 19.05%Good 19.05% Good | 0.17Excellent 0.2 Excellent | 15.00%Excellent 15.00% Excellent | 20.23%Excellent 20.23% Excellent | 0.00% |
Aarti Pharmalabs LtdAarti Pharmalab... AARTIPHARM • 543748 | 9.1/100 | ₹672.70₹673 | ₹6511.24₹6511.24 | 36.83Average 36.8 Average | 8.59%Poor 8.59% Poor | 10.70%Average 10.70% Average | 0.36Excellent 0.4 Excellent | — — | — — | 0.70% |
38/100 | ₹1444.90₹1445 | ₹4726.65₹4726.65 | — — | -15.00%Poor -15.00% Poor | -8.47%Poor -8.47% Poor | 0.39Excellent 0.4 Excellent | — — | 38.41%Excellent 38.41% Excellent | 0.07% | |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price193163.97 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Biocon Ltd share price70826.50 Cr
- Abbott India Ltd share price58692.31 Cr
- JB Chemicals & Pharmaceuticals Ltd share price40248.14 Cr
Cipla Limited PE Ratio History
Historical price-to-earnings ratio for CIPLA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹65.24 | ₹1511.30 | 23.2x |
| FY 2024 | ₹51.01 | ₹1529.00 | 30x |
| FY 2023 | ₹34.69 | ₹1246.30 | 35.9x |
| FY 2022 | ₹31.17 | ₹1075.95 | 34.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Cipla Limited Dividend History
Annual cash dividends paid by CIPLA — dividend yield 0.90%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1049.83 Cr |
| FY 2024 | ₹686.17 Cr |
| FY 2023 | ₹403.50 Cr |
| FY 2022 | ₹403.35 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Cipla Limited Quarterly Performance
Latest quarterly metrics for CIPLA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
2.33%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-39.19%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.01%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.03%
Compounded annual net profit growth over 5 years
Cipla Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CIPLA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Cipla Limited Financial Statements
Annual income statement, balance sheet and cash flow for Cipla Limited (CIPLA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Cipla Limited
About CIPLA (Cipla Limited)
Cipla Ltd is a global pharmaceutical powerhouse, recognized for its commitment to providing affordable and accessible healthcare solutions. From its state-of-the-art manufacturing ...facilities, Cipla formulates and distributes a wide range of medications, catering to diverse medical needs across the globe. The company distinguishes itself through its dedication to innovation, constantly pushing the boundaries of pharmaceutical research and development to create novel treatments and improve existing therapies. With a strong emphasis on quality and patient well-being, Cipla has established itself as a trusted partner for healthcare professionals and patients alike, ensuring that life-saving medications reach those who need them most. Cipla's operations are strategically structured, encompassing the development, production, and marketing of a comprehensive portfolio of pharmaceutical products. Their offerings range from complex generics to innovative formulations, all adhering to the highest international quality standards. The company's diverse therapeutic focus covers critical areas such as respiratory diseases, oncology, HIV/AIDS, and cardiovascular health, demonstrating its commitment to addressing some of the world's most pressing health challenges. Through strategic partnerships and a robust distribution network, Cipla ensures that its products are readily available in both developed and emerging markets, contributing to improved health outcomes on a global scale. Driven by a mission to make a difference in people's lives, Cipla continually invests in cutting-edge technologies and sustainable manufacturing practices. The company's commitment to corporate social responsibility is evident in its various initiatives aimed at promoting healthcare access, supporting community development, and protecting the environment. By fostering a culture of innovation, collaboration, and ethical conduct, Cipla attracts and retains top talent, enabling it to maintain its competitive edge in the dynamic pharmaceutical industry. Through its unwavering dedication to quality, affordability, and social impact, Cipla continues to shape the future of healthcare and improve the lives of millions worldwide.
Company Details
Key Leadership
Corporate Events
CIPLA Share Price: Frequently Asked Questions
What is the current share price of Cipla Limited?
Cipla Limited (CIPLA) trades at ₹1431.10 on NSE and BSE. Market cap ₹1.16L (Cr). Educational data only.
What is the P/E ratio of Cipla Limited?
Cipla Limited has a P/E of 34.45x vs industry average 34.89x.
What is the Bull Run score for Cipla Limited?
Cipla Limited has a Bull Run score of 40.2/100 based on 25+ financial parameters.
Does Cipla Limited pay dividends?
Cipla Limited has a dividend yield of 0.90%. Past dividends don't guarantee future payments.
What is the ROE of Cipla Limited?
Cipla Limited has ROE of 11.82%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Cipla Limited?
Cipla Limited has debt-to-equity of 0.01.
Is Cipla Limited a good investment?
Bull Run gives Cipla Limited a score of 40.2/100. This is not investment advice — consult a SEBI-registered advisor.